Nasdaq

Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic ...

PHILADELPHIA, Oct. 26, 2023 /PRNewswire/ -- Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, and its Joint Venture partner, Ocean ...
Nasdaq

Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a ...

Providence, Rhode Island, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research ...
Yahoo Finance

Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b ...

VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported In the majority of ...
GEN

Highly Multiplexed Analysis of Membrane Proteins for Biologics Development Using Virion Display Technology

Membrane proteins are key targets for therapeutic intervention using antibody biologics. Over 60% of FDA-approved drugs act on these proteins. Studying them is challenging because the proteins must be ...